Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.
Psychiatr Q
; 83(3): 311-24, 2012 Sep.
Article
en En
| MEDLINE
| ID: mdl-22101738
ABSTRACT
Twenty-three adolescents with psychotic disorders, aged from 13 to 18 years, participated in a 12-week open label trial (17 adolescents completed the study) in order to examine the impact of quetiapine on clinical status and cognitive functions (encompassing processing speed, attention, short-term memory, long-term memory and executive function). An improvement in Clinical Global Impression and Positive and Negative Symptom Scale (P's ≤ 0.001) was observed. In addition, after controlling for amelioration of symptoms, a significant improvement was observed on one executive function (P = 0.044; Trail Making Part B). The remaining cognitive abilities showed stability. In addition, we observed an interaction between quetiapine doses (>300 mg/day or <300 mg/day) and time, where lower doses showed more improvement in verbal short-term memory (P = 0.048), inhibition abilities (P = 0.038) and positive symptoms (P = 0.020). The neuropsychological functioning of adolescents with psychotic disorders remained mainly stable after 12 weeks of treatment with quetiapine. However, lower doses seemed to have a better impact on two components of cognition (inhibition abilities and verbal short-term memory) and on positive symptoms.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Trastornos Psicóticos
/
Esquizofrenia
/
Psicología del Esquizofrénico
/
Antipsicóticos
/
Trastornos del Conocimiento
/
Dibenzotiazepinas
Tipo de estudio:
Prognostic_studies
Límite:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Año:
2012
Tipo del documento:
Article